nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—HTR1B—attention deficit hyperactivity disorder	0.428	0.53	CbGaD
Dihydroergotamine—ADRA2A—attention deficit hyperactivity disorder	0.379	0.47	CbGaD
Dihydroergotamine—HTR6—forebrain—attention deficit hyperactivity disorder	0.00254	0.0736	CbGeAlD
Dihydroergotamine—HTR1B—forebrain—attention deficit hyperactivity disorder	0.00153	0.0444	CbGeAlD
Dihydroergotamine—HTR1D—forebrain—attention deficit hyperactivity disorder	0.00148	0.0429	CbGeAlD
Dihydroergotamine—HTR6—nervous system—attention deficit hyperactivity disorder	0.00138	0.0399	CbGeAlD
Dihydroergotamine—HTR2B—forebrain—attention deficit hyperactivity disorder	0.00138	0.0399	CbGeAlD
Dihydroergotamine—HTR6—central nervous system—attention deficit hyperactivity disorder	0.00133	0.0385	CbGeAlD
Dihydroergotamine—Ergoloid mesylate—DRD1—attention deficit hyperactivity disorder	0.00131	0.141	CrCbGaD
Dihydroergotamine—HTR1B—cardiovascular system—attention deficit hyperactivity disorder	0.00129	0.0375	CbGeAlD
Dihydroergotamine—HTR1D—cardiovascular system—attention deficit hyperactivity disorder	0.00125	0.0363	CbGeAlD
Dihydroergotamine—HTR1A—forebrain—attention deficit hyperactivity disorder	0.00123	0.0358	CbGeAlD
Dihydroergotamine—HTR2B—cardiovascular system—attention deficit hyperactivity disorder	0.00116	0.0338	CbGeAlD
Dihydroergotamine—Bromocriptine—DRD5—attention deficit hyperactivity disorder	0.00114	0.123	CrCbGaD
Dihydroergotamine—Bromocriptine—ADRA2C—attention deficit hyperactivity disorder	0.00108	0.116	CrCbGaD
Dihydroergotamine—HTR6—brain—attention deficit hyperactivity disorder	0.00105	0.0305	CbGeAlD
Dihydroergotamine—HTR1A—cardiovascular system—attention deficit hyperactivity disorder	0.00104	0.0303	CbGeAlD
Dihydroergotamine—HTR1B—midbrain—attention deficit hyperactivity disorder	0.00101	0.0293	CbGeAlD
Dihydroergotamine—HTR1D—midbrain—attention deficit hyperactivity disorder	0.000977	0.0284	CbGeAlD
Dihydroergotamine—Ergoloid mesylate—DRD2—attention deficit hyperactivity disorder	0.000926	0.0996	CrCbGaD
Dihydroergotamine—ADRA2A—forebrain—attention deficit hyperactivity disorder	0.000864	0.0251	CbGeAlD
Dihydroergotamine—HTR1B—nervous system—attention deficit hyperactivity disorder	0.00083	0.0241	CbGeAlD
Dihydroergotamine—HTR1A—midbrain—attention deficit hyperactivity disorder	0.000814	0.0236	CbGeAlD
Dihydroergotamine—HTR1D—nervous system—attention deficit hyperactivity disorder	0.000803	0.0233	CbGeAlD
Dihydroergotamine—HTR1B—central nervous system—attention deficit hyperactivity disorder	0.000799	0.0232	CbGeAlD
Dihydroergotamine—HTR1D—central nervous system—attention deficit hyperactivity disorder	0.000773	0.0224	CbGeAlD
Dihydroergotamine—HTR2B—nervous system—attention deficit hyperactivity disorder	0.000747	0.0217	CbGeAlD
Dihydroergotamine—HTR2B—central nervous system—attention deficit hyperactivity disorder	0.000719	0.0209	CbGeAlD
Dihydroergotamine—HTR1A—nervous system—attention deficit hyperactivity disorder	0.000669	0.0194	CbGeAlD
Dihydroergotamine—HTR1A—central nervous system—attention deficit hyperactivity disorder	0.000645	0.0187	CbGeAlD
Dihydroergotamine—HTR1B—brain—attention deficit hyperactivity disorder	0.000634	0.0184	CbGeAlD
Dihydroergotamine—HTR1A—cerebellum—attention deficit hyperactivity disorder	0.00063	0.0183	CbGeAlD
Dihydroergotamine—HTR1D—brain—attention deficit hyperactivity disorder	0.000614	0.0178	CbGeAlD
Dihydroergotamine—Bromocriptine—DRD4—attention deficit hyperactivity disorder	0.000584	0.0629	CrCbGaD
Dihydroergotamine—HTR2B—brain—attention deficit hyperactivity disorder	0.000571	0.0166	CbGeAlD
Dihydroergotamine—ADRA2A—midbrain—attention deficit hyperactivity disorder	0.000571	0.0166	CbGeAlD
Dihydroergotamine—Ergotamine—HTR1B—attention deficit hyperactivity disorder	0.000538	0.0579	CrCbGaD
Dihydroergotamine—Bromocriptine—HTR1B—attention deficit hyperactivity disorder	0.000519	0.0558	CrCbGaD
Dihydroergotamine—HTR1A—brain—attention deficit hyperactivity disorder	0.000512	0.0149	CbGeAlD
Dihydroergotamine—Bromocriptine—DRD3—attention deficit hyperactivity disorder	0.000504	0.0542	CrCbGaD
Dihydroergotamine—Bromocriptine—DRD1—attention deficit hyperactivity disorder	0.000494	0.0532	CrCbGaD
Dihydroergotamine—ABCB1—forebrain—attention deficit hyperactivity disorder	0.000482	0.014	CbGeAlD
Dihydroergotamine—Ergotamine—ADRA2A—attention deficit hyperactivity disorder	0.000476	0.0513	CrCbGaD
Dihydroergotamine—ADRA2A—nervous system—attention deficit hyperactivity disorder	0.000469	0.0136	CbGeAlD
Dihydroergotamine—Bromocriptine—ADRA2A—attention deficit hyperactivity disorder	0.000459	0.0494	CrCbGaD
Dihydroergotamine—ADRA2A—central nervous system—attention deficit hyperactivity disorder	0.000452	0.0131	CbGeAlD
Dihydroergotamine—ADRA2A—cerebellum—attention deficit hyperactivity disorder	0.000442	0.0128	CbGeAlD
Dihydroergotamine—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.000407	0.0118	CbGeAlD
Dihydroergotamine—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000369	0.0107	CbGeAlD
Dihydroergotamine—Ergotamine—DRD2—attention deficit hyperactivity disorder	0.000361	0.0389	CrCbGaD
Dihydroergotamine—ADRA2A—brain—attention deficit hyperactivity disorder	0.000359	0.0104	CbGeAlD
Dihydroergotamine—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.000356	0.0103	CbGeAlD
Dihydroergotamine—Bromocriptine—DRD2—attention deficit hyperactivity disorder	0.000348	0.0375	CrCbGaD
Dihydroergotamine—ABCB1—midbrain—attention deficit hyperactivity disorder	0.000318	0.00923	CbGeAlD
Dihydroergotamine—Ergotamine—HTR2A—attention deficit hyperactivity disorder	0.000279	0.0301	CrCbGaD
Dihydroergotamine—Bromocriptine—HTR2A—attention deficit hyperactivity disorder	0.000269	0.029	CrCbGaD
Dihydroergotamine—ABCB1—nervous system—attention deficit hyperactivity disorder	0.000261	0.00759	CbGeAlD
Dihydroergotamine—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.000252	0.00731	CbGeAlD
Dihydroergotamine—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.000246	0.00714	CbGeAlD
Dihydroergotamine—ABCB1—brain—attention deficit hyperactivity disorder	0.0002	0.0058	CbGeAlD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	8.11e-05	0.000541	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	8.1e-05	0.00054	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	8.1e-05	0.00054	CbGpPWpGaD
Dihydroergotamine—HTR1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	7.96e-05	0.000531	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	7.94e-05	0.00053	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	7.77e-05	0.000518	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	7.74e-05	0.000516	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	7.71e-05	0.000514	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	7.61e-05	0.000507	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	7.57e-05	0.000505	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	7.55e-05	0.000504	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	7.53e-05	0.000502	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	7.53e-05	0.000502	CbGpPWpGaD
Dihydroergotamine—HTR2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	7.48e-05	0.000499	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	7.31e-05	0.000487	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	7.29e-05	0.000486	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	7.28e-05	0.000486	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	7.17e-05	0.000478	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	7.08e-05	0.000472	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	7.08e-05	0.000472	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	7.07e-05	0.000472	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	7.02e-05	0.000468	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	7e-05	0.000467	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	6.87e-05	0.000458	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	6.86e-05	0.000457	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	6.81e-05	0.000454	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	6.59e-05	0.00044	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	6.5e-05	0.000434	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	6.46e-05	0.000431	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	6.45e-05	0.00043	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	6.42e-05	0.000428	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	6.37e-05	0.000425	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	6.37e-05	0.000424	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	6.32e-05	0.000421	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	6.24e-05	0.000416	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	6.24e-05	0.000416	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	6.19e-05	0.000413	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	6.18e-05	0.000412	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	6.17e-05	0.000411	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	6.14e-05	0.000409	CbGpPWpGaD
Dihydroergotamine—ABCB1—HIF-1-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	6.07e-05	0.000405	CbGpPWpGaD
Dihydroergotamine—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	6.07e-05	0.000404	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	6.06e-05	0.000404	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	6.06e-05	0.000404	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	5.94e-05	0.000396	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	5.94e-05	0.000396	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	5.92e-05	0.000395	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	5.86e-05	0.000391	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	5.79e-05	0.000386	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	5.75e-05	0.000383	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	5.73e-05	0.000382	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	5.7e-05	0.00038	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	5.7e-05	0.00038	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	5.64e-05	0.000376	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	5.61e-05	0.000374	CbGpPWpGaD
Dihydroergotamine—HTR1A—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	5.61e-05	0.000374	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	5.59e-05	0.000373	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	5.59e-05	0.000372	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	5.57e-05	0.000372	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	5.57e-05	0.000371	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	5.56e-05	0.000371	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	5.56e-05	0.000371	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	5.55e-05	0.00037	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	5.52e-05	0.000368	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	5.5e-05	0.000367	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	5.47e-05	0.000365	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	5.47e-05	0.000365	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	5.43e-05	0.000362	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	5.43e-05	0.000362	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	5.43e-05	0.000362	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	5.41e-05	0.000361	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	5.4e-05	0.00036	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	5.39e-05	0.00036	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	5.37e-05	0.000358	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	5.36e-05	0.000358	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	5.33e-05	0.000355	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	5.32e-05	0.000355	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	5.32e-05	0.000355	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	5.25e-05	0.00035	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	5.25e-05	0.00035	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	5.24e-05	0.000349	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	5.22e-05	0.000348	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	5.22e-05	0.000348	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	5.18e-05	0.000346	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	5.18e-05	0.000345	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	5.13e-05	0.000342	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	5.1e-05	0.00034	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	5.08e-05	0.000339	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	5.07e-05	0.000338	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	5.06e-05	0.000337	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	5.03e-05	0.000336	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	5.02e-05	0.000335	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	5e-05	0.000333	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	5e-05	0.000333	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	5e-05	0.000333	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	4.97e-05	0.000331	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4.93e-05	0.000329	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	4.93e-05	0.000329	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	4.91e-05	0.000328	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	4.91e-05	0.000327	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.9e-05	0.000327	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	4.89e-05	0.000326	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	4.87e-05	0.000325	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	4.85e-05	0.000323	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	4.83e-05	0.000322	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.81e-05	0.000321	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	4.77e-05	0.000318	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	4.77e-05	0.000318	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	4.76e-05	0.000318	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.76e-05	0.000317	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.62e-05	0.000308	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	4.61e-05	0.000308	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	4.6e-05	0.000306	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4.58e-05	0.000305	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	4.57e-05	0.000305	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	4.54e-05	0.000303	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	4.54e-05	0.000302	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	4.48e-05	0.000299	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	4.44e-05	0.000296	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.26e-05	0.000284	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	4.17e-05	0.000278	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.16e-05	0.000277	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.14e-05	0.000276	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.12e-05	0.000275	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	4.12e-05	0.000274	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.05e-05	0.00027	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	4.05e-05	0.00027	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	4.05e-05	0.00027	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	4.02e-05	0.000268	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4e-05	0.000267	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	4e-05	0.000266	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.97e-05	0.000265	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.89e-05	0.000259	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.86e-05	0.000258	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.79e-05	0.000253	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.78e-05	0.000252	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.77e-05	0.000251	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.74e-05	0.00025	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.74e-05	0.000249	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.73e-05	0.000249	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.69e-05	0.000246	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.68e-05	0.000245	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.63e-05	0.000242	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	3.63e-05	0.000242	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.6e-05	0.00024	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	3.53e-05	0.000235	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	3.5e-05	0.000233	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.46e-05	0.000231	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	3.43e-05	0.000228	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.38e-05	0.000226	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.34e-05	0.000223	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.32e-05	0.000221	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.29e-05	0.000219	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.27e-05	0.000218	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.25e-05	0.000217	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.24e-05	0.000216	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	3.22e-05	0.000215	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	3.2e-05	0.000214	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.19e-05	0.000212	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	3.18e-05	0.000212	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.14e-05	0.00021	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.12e-05	0.000208	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	3.11e-05	0.000207	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.08e-05	0.000206	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.06e-05	0.000204	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.04e-05	0.000203	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.03e-05	0.000202	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3e-05	0.0002	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.99e-05	0.000199	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.96e-05	0.000198	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.94e-05	0.000196	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.94e-05	0.000196	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.93e-05	0.000195	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.92e-05	0.000195	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.91e-05	0.000194	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.9e-05	0.000194	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.9e-05	0.000193	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.88e-05	0.000192	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.86e-05	0.00019	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.85e-05	0.00019	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	2.82e-05	0.000188	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.82e-05	0.000188	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.81e-05	0.000188	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.81e-05	0.000187	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.73e-05	0.000182	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.7e-05	0.00018	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.69e-05	0.000179	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—TPH2—attention deficit hyperactivity disorder	2.68e-05	0.000179	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.68e-05	0.000179	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.68e-05	0.000179	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.68e-05	0.000179	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.66e-05	0.000177	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.65e-05	0.000176	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—DPYD—attention deficit hyperactivity disorder	2.64e-05	0.000176	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.62e-05	0.000175	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.61e-05	0.000174	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	2.59e-05	0.000173	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.47e-05	0.000164	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.46e-05	0.000164	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.45e-05	0.000164	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.37e-05	0.000158	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.28e-05	0.000152	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.21e-05	0.000147	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.21e-05	0.000147	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.17e-05	0.000145	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.15e-05	0.000143	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.15e-05	0.000143	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.05e-05	0.000137	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2e-05	0.000133	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.93e-05	0.000129	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.89e-05	0.000126	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.88e-05	0.000125	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.86e-05	0.000124	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	1.86e-05	0.000124	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.86e-05	0.000124	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.84e-05	0.000123	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	1.83e-05	0.000122	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.79e-05	0.00012	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.74e-05	0.000116	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.73e-05	0.000115	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—EP300—attention deficit hyperactivity disorder	1.72e-05	0.000115	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.7e-05	0.000113	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.69e-05	0.000112	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.66e-05	0.00011	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—COMT—attention deficit hyperactivity disorder	1.63e-05	0.000108	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—MAOA—attention deficit hyperactivity disorder	1.61e-05	0.000108	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.57e-05	0.000105	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.48e-05	9.89e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.41e-05	9.42e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.4e-05	9.34e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	1.14e-05	7.62e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.14e-05	7.62e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	1.12e-05	7.5e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	1.12e-05	7.5e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	1.12e-05	7.44e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.1e-05	7.34e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.05e-05	6.97e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1e-05	6.68e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—EP300—attention deficit hyperactivity disorder	9.95e-06	6.63e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	9.74e-06	6.49e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	9.15e-06	6.1e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	9.14e-06	6.1e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	8.7e-06	5.8e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.42e-06	4.95e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—EP300—attention deficit hyperactivity disorder	6.97e-06	4.65e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	6.93e-06	4.62e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	6.88e-06	4.59e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.83e-06	3.89e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	4.82e-06	3.22e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	2.97e-06	1.98e-05	CbGpPWpGaD
